ProxyMed acquires MDP Corp. Md. The NIH granted Viragen the exclusive commercial rights to the use of a monoclonal antibody that recognizes Notch-1 protein. Cells usually die when they get infected with bacteria or viruses or have outlived their useful purpose, according to the company. When this occurs, death is signaled by a special gene in the cell, which then produces Notch proteins.
Notch proteins affect the fate of cells.
Viragen researches, develops and manufactures drugs for the treatment of many life-threatening diseases such as hepatitis C, multiple sclerosis and cancer. Earliest info on new businesses, homeowners Sales Prospecting Center Real info, real opportunities. Hire South Florida Fill an opening, find a job Internet Directory Local businesses on the web Merchant Services Start accepting credit cards online. Office Products Special deals on equipment, supplies.